Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
Brett King(Yale Cancer Center), James V. Cassella(Trevi Therapeutics (United States)), Charles Lynde(University of Toronto), Catherine Maari(Université de Montréal), Maryanne M. Senna(Lahey Hospital and Medical Center), Marni Wiseman(University of Manitoba), Colleen Hamilton(Concert Pharmaceuticals (United States)), Vimal H. Prajapati(University of Calgary), Paweł Brzewski(Jagiellonian University), Sameh Hanna(University of Toronto), Sheetal Sapra(Institute of Cosmetic and Laser Surgery), Matthew Zirwas(Ohio University), Lawrence Osman, Natasha Atanaskova Mesinkovska(University of California, Irvine)
Cited by 79
Related Papers
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
|British Journal of Dermatology|2020|590
Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine
|The British Journal of Psychiatry|2011|153
The design and calibration of a startle measurement system
|Physiology & Behavior|1986|142
Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo‐controlled clinical trial with inhaled loxapine
|Bipolar Disorders|2012|124
Opposing roles of the amygdala and dorsolateral periaqueductal gray in fear-potentiated startle
|Neuroscience & Biobehavioral Reviews|1997|108